Scientist create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
Entries by Thomas Gabrielczyk
Scientists create non-digestible aptamer
/in News/by Thomas GabrielczykGerman researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
SynaptixBio Ltd gets FDA ODD for leukodystrophy
/in News/by Thomas GabrielczykRare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
/in News/by Thomas GabrielczykPierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Bayer SE secures rights to in €310m deal
/in News/by Thomas GabrielczykBayer AG has purchased European commercialisation rights for the transthyretin amyloid cardiomyopathy candidate acoramidis from BridgeBio Inc.<i> </i>
Swiss vaccine developer Limma Tech get CARB-X grant
/in News/by Thomas GabrielczykSwiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Curve Therapeutics raises £40.5m in Series A financing
/in News/by Thomas GabrielczykIntracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
Pacifico Biolabs raises US$3.3m in pre-seed round
/in News/by Thomas GabrielczykGerman foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.<br /><br /><br /><br />
Gene therapy supplier MIP Discovery closes £7M Series A financing
/in News/by Thomas GabrielczykMIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.
Vidac Pharma Holding plc reports preclinical proof of principle
/in News/by Thomas GabrielczykLondon-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.